The active ingredient of METALYSE (tenecteplase) is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modification at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher f...

thrombolytic therapy, an appropriate treatment option , if primary angioplasty is not available for the treatment of Acute Myocardial Infarction patients in the early hours after the onset of the symptoms. The aim of this study was to evaluate the safety and effectiveness of the tenecteplase drug vs alteplase  in the treatment of STEMI patients. We searched the PubMed, cochrane library, Web Of ...

Background We report the interim results of a process improvement initiative at comprehensive stroke center in which all tPA (tissue‐type plasminogen activator)–eligible patients were given tenecteplase for acute ischemic stroke. Methods retrospectively analyzed prospectively maintained single‐center registry consecutive with treated our emergency department or transferred further care. Patient...

pattern — no improvement in early reperfusion, but there was a reduced rate of recurrent myocardial infarction. In streptokinase-treated patients, TIMI grade 3 flow at 20–28 h later tended to be higher in patients treated with dalteparin (68% vs 51% for unfractionated heparin, P=0·10), and the number of ischaemic episodes on continuous ECG monitoring was lower (16% vs 38%, P=0·04) with similar ...

BACKGROUND Alteplase is the only approved thrombolytic agent for acute ischaemic stroke. The overall benefit from alteplase is substantial, but some evidence indicates that alteplase also has negative effects on the ischaemic brain. Tenecteplase may be more effective and less harmfull than alteplase, but large randomised controlled phase 3 trials are lacking. The Norwegian Tenecteplase Stroke T...


 Both included economic evaluation studies (1 from Iran and 1 Australia) found that tenecteplase was the dominant treatment strategy (i.e., lower costs higher benefit) compared with alteplase over a lifetime horizon.

Background: Acute myocardial infarction (AMI) is the leading cause of death throughout the world. One of the standard approaches to treatment of AMI is fibrinolysis. The study was conducted to evaluate the clinical efficacy of tenecteplase versus reteplase through network meta-analysis for AMI. Methods: Randomized trials were comprehensively searched in PubMed, Scopus, Cochrane library, a...

Urgent reperfusion of the ischaemic brain is the aim of stroke treatment and there has been ongoing research to find a drug that can promote vessel recanalisation more completely and with less side effects. In this review article, the major studies which have validated the use and safety of tPA are discussed. The safety and efficacy of other thrombolytic and anticoagulative agents such as tenec...